Advertisement

Recombinant Immunotoxins for Treating Cancer

  • Ira PastanEmail author
  • Mitchell Ho
Protocol
Part of the Springer Protocols Handbooks book series (SPH)

Abstract

Targeted antibody therapy represents a promising approach for the treatment of cancer. However, antibodies that bind to cancer cells are often, by themselves, not cytotoxic. Recombinant immunotoxins (RITs) are chimeric proteins composed of the variable fragment (Fv) of a monoclonal antibody fused to a portion of a powerful bacterial toxin. The Fv replaces the cell-binding domain of the toxin and directs the toxin to cancer cells that express an internalizing target antigen. RITs are very potent and are able to kill cells that are resistant to standard chemotherapy. Results from clinical trials indicate that RITs that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.

Keywords

Human Serum Albumin Fast Protein Liquid Chromatography Refold Buffer Pseudomonas Exotoxin MonoQ Column 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Portions of the manuscript have been previously published in: Pastan I, Beers R, and Bera TK (2003) Recombinant immunotoxins in the treatment of cancer. Lo BKC (ed) Methods in molecular biology, vol 248. Antibody engineering methods and protocols, New Jersey, Humana Press, pp 503–518

References

  1. Brinkmann U, Reiter Y, Jung S-H, Lee B, Pastan I (1993) A recombinant immunotoxin containing a disulfide-stabilized Fv fragment (dsFv). Proc Natl Acad Sci USA 90:7538–7542PubMedCrossRefGoogle Scholar
  2. Hassan R, Bullock S, Premkumar A et al (2007) Phase I study of SS1P, a recombinant antimesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelinexpressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144–5149PubMedCrossRefGoogle Scholar
  3. Ho M, Kreitman RJ, Onda M, Pastan I (2005) In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 280:607–617PubMedCrossRefGoogle Scholar
  4. Hwang J, FitzGerald DJP, Adhya S, Pastan I (1987) Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48:129–136PubMedCrossRefGoogle Scholar
  5. Kreitman RJ, Wilson WH, White JD et al (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622–1636PubMedGoogle Scholar
  6. Kreitman RJ, Wilson WH, Bergeron K et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241–247PubMedCrossRefGoogle Scholar
  7. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565PubMedCrossRefGoogle Scholar
  8. Studier FW, Moffatt BA (1986) Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189:113–130PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Laboratory of Molecular BiologyNational Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations